


IN THE CLAIMS:

The following is a complete listing of the claims:

Please cancel claims 1-100.

Please add new claims 101-112.

101. (New) A method for treating cancer which comprises administering to a mammal a therapeutically-effective combination of chemotherapeutic agents comprising (1) at least one anti-metabolite selected from capecitabine and/or 5-fluorouracil, and (2) Compound (1), having the formula,




102. (New) The method according to claim 101, wherein the anti-metabolite is capecitabine administered following the administration of Compound 1.

103. (New) The method according to claim 101, wherein the anti-metabolite is capecitabine administered before the administration of Compound 1.

104. (New) The method according to claim 101, wherein the anti-metabolite is capecitabine administered substantially simultaneously with the administration of Compound 1.

105. (New) The method according to claim 101, comprising the treatment of cancerous solid tumors.
106. (New) The method according to claim 101, comprising the treatment of refractory tumors.
107. (New) The method according to claim 101, wherein the cancer is metastatic breast cancer.
108. (New) The method according to claim 101, wherein the cancer is lung cancer.
109. (New) The method according to claim 101, wherein the cancer is prostate cancer.
110. (New) The method according to claim 101, wherein the cancer is pancreatic cancer.
- 111 (New). A pharmaceutical product for administering a combination of anti-proliferative agents to a mammal, the product comprising in a first package an anti-metabolite selected from capecitabine and/or 5-fluorouracil, and in a second package, Compound (1), which is,



- 112 (New). The product according to Claim 111 wherein the anti-metabolite is capecitabine.